ARCHIVES

Zaltrap Economics 101: The Pricing And Repricing of an Expensive Drug

This article is from The Cancer Letter archive.

Vol. 38 No. 43 | November 16, 2012

Download PDF Visit The Full Archive

Related Articles

In Brief: Twenty-Nine Percent Of Approved Organ Systems Applications Funded In February, May Cycles

November 4, 1983

Is the Concept of National Chain Of Outpatient Centers Still Viable?

May 2, 1997

Phase III Custirsen/Docetaxel/Prednisone Trial Fails Primary Endpoint of Overall Survival

April 25, 2014

NCI Rethinks Cancer Center Grants

March 14, 2014

Group Chairmen Approve Policy On Industry Support; NCI Turns Down Request To “Launder” Contributions

December 16, 1983

Advisors OK Planning Grants In Breast Cancer For Cancer Centers

July 9, 1993